Last reviewed · How we verify
BNT323
At a glance
| Generic name | BNT323 |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer (PHASE1, PHASE2)
- A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (PHASE3)
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer (PHASE3)
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT323 CI brief — competitive landscape report
- BNT323 updates RSS · CI watch RSS
- BioNTech SE portfolio CI